Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells

Cancer Investigation

Volumn 17, Issue 1, 1999, Pages 10-18

  Rajah, Talitha T ^a   Pento, J Thomas ^a,b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiestrogen; Breast cancer; Invasion; Laminin; Metastasis

Indexed keywords

1,1 DICHLORO 2,3 DIPHENYLCYCLOPROPANE; ANTIESTROGEN; FULVESTRANT; LAMININ; TAMOXIFEN;

ARTICLE; BASEMENT MEMBRANE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL INVASION; DRUG EFFECT; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL;

EID: 0033005354     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1080/07357909909011712     Document Type: Article

References (40)

1. Liotta LA: Tumor invasion and metastases: Role of the basement membrane. Am J Pathol 117:339-348, 1984.
2. Poste G, Fidler IJ: The pathogenesis of cancer metastasis. Nature 283:139-146, 1980.
3. Reich R. Stratford B, Klein K, et al: In: Inhibitors of Collagenase IV and Cell Adhesion Reduce the Invasive Activity of Malignant Tumor Cells, London, Ciba Foundation Symposium, 1988, pp 193-210.
4. Monteagudo C, Merino MJ, San-Juan J, et al: Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol 136:585-592, 1990.
5. Nicholson RI, Borthwick N, Daniel CP, et al: In: Nonsteroidal Antiestrogens: Molecular Pharmacology and Antitumor Activity, edited by RL Sutherland, VC Jordan, New York, Academic Press, 1982, pp 281-301.
6. Santen RJ, Manni A, Harvey H, et al: Endocrine treatment of breast cancer in women. Endocrinol Rev 11:221-265, 1990.
7. Jordan VC, Murphy C: Endocrine pharmacology of antiestrogens as antitumor agents. Endocrinol Rev 11:578, 1990.
8. Fentiman IS, Powles TJ: Tamoxifen and benign breast problems. Lancet 2:1070-1072, 1987.
9. Fornander T, Cedermark B, Mattsson A, et al: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117-119, 1989.
10. Boccaardo F, Bruzzi P, Rubagotti A, et al: Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38:281-285, 1981.
11. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogen. Cancer Treat Rep 69:237-238, 1985.
12. Osborne CK, Coronado EB, Robinson JR: Human breast cancer in athymic mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 2:1189-1196, 1987.
13. Clarke R, Thompson EW, Leonessa F, et al: Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat 24:227-239, 1993.
14. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumor in athymic mouse after long-term tamoxifen administration. Cancer Res 48:5183-5188, 1988.
15. Wakeling AE, Bowler J: Novel antiestrogens without partial agonist activity. J Steroid Biochem 31:645-653, 1988.
16. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with new benzothiophene-derived antiestrogen. Life Sci 32: 1031-1036, 1983.
17. Day BW, Magarian RA, Jain PT, et al: Synthesis and biological evaluation of a series of 1,1-Dichloro-2,2,3-triaryl cyclopropanes as pure antiestrogens. J Med Chem 34:842-851, 1991.
18. Griffin MT, Magarian RA, Jain P, et al: Synthesis and biological evaluation of a series of gem-dichlorocyclopropanes as antitumor agents. Anti-Cancer Drug Design 7:49-66, 1992.
19. Stobaugh JF, Magarian RA, Pento JT: Synthesis and biological evaluation of gem-dichlorocyclopropyl analogs of stilbene congeners as potential antiestrogens. J Pharm Sci 71:1126-1129, 1982.
20. Pento JT, Magarian RA, King MMA: Comparison of the efficacy for antitumor activity of nonsteroidal antiestrogens Analog II and tamoxifen in DMBA induced rat mammary tumors. Cancer Lett 15:261-269, 1982.
21. King MM, Pento JT, Magarian RA: The interaction of dietary fat and antiestrogen treatment on DMBA-induced mammary tumors in the rat. Nutrition Cancer 7:239-249, 1985.
22. King MM, Magarian RA, Terao J, et al: Effect of nonsteroidal antiestrogen, Analog II and tamoxifen on a metastatic transplantable rat mammary tumor. J Natl Cancer Inst 74:447-451, 1985.
23. Jain PT, Pento JT, Magarian RA, et al: Cytotoxicity of Analog II in human breast cancer cells in culture. Toxicologist 11:157, 1991.
24. Jain PT, Pento JT, Chissoe III, et al: The effects on a series of novel antiestrogens on the morphology of human breast cancer cells using scanning electron microscopy (SEM). FASEB J 5: A692, 1991.
25. Jain PT, Pento JT: A vehicle for the evaluation of hydrophobic compounds in cell culture. Res Commun Chem Path Pharm 74: 105-116, 1991.
26. Thompson EW, Brunner N, Torri J: The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis 11:15-26, 1993.
27. Charpin C, Lissitzky JC, Jacquemier J, et al: Immunohistochemical detection of laminin in 98 human breast carcinomas: A light and electron microscopic study. Hum Pathol 17:335-365, 1986.
28. Tsubara A, Shikata N, Inui T, et al: Immunohistochemical localization of myoepithelial cells and basement membrane in normal, benign and malignant human breast lesions. Virchow Arch (A) 413:133-139, 1988.
29. Terranova VP, Rao CN, Kabelic T, et al: Laminin receptor on human breast carcinoma cells. Proc Natl Acad Sci USA 80:444-451, 1983.
30. Kramer R, McDonald KA, Vu MP: Human melanoma cells express a novel integrin receptor for laminin. J Biol Chem 264: 15642-15649, 1989.
31. Hand PH, Thor A, Scholm J, et al: Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody. Cancer Res 45:2713-2719, 1985.
32. Yow H, Wong JM, Chen HS, et al: Increased mRNA expression of a laminin-binding protein in human colon carcinomas: Complete sequence of a full-length cDNA encoding the protein. Proc Natl Acad Sci USA 8:6394-6398, 1988.
33. Bae S-N, Arand G, Azzam H, et al: Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in matrigel-based in vitro assays. Breast Cancer Res Treat 24: 241-255, 1993.
34. Castronovo V, Taraboletti G, Liotta LA, et al: Modulation of laminin receptor by estrogen and progestin in human breast cancer cell lines. J Natl Cancer Inst 81:781-788, 1989.
35. Thompson EW, Katz D, Shima TB, et al: ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res 49:6929-6934, 1989.
36. Thompson EW, Reich R, Shima TB, et al: Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by anti-estrogens. Cancer Res 48:6764-6768, 1988.
37. Shi YE, Torri J, Yieh L, et al: Expression of 67 kDA laminin receptor in human breast cancer cells: regulation by progestins. Clin Exp Metastasis 11:251-261, 1993.
38. Coezy E, Borgna JL, Rochefort H: Tamoxifen and metabolites in MCF-7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317-323, 1982.
39. Manni A, Wright C, Buck H: Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar. Breast Cancer Res Treat 20:43-52, 1991.
40. Knabbe C, Lippman ME, Wakefield LM, et al: Evidence that transforming growth factor is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428, 1987.